SAN DIEGO, February 15, 2022 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development.
“I am pleased to welcome Eef Schimmelpennink to Pipeline’s Board of Directors,” said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. “Eef is a renowned leader in the life-sciences industry whose cross-functional leadership experience will be invaluable to Pipeline as we advance our neuroregeneration platform.”
“Pipeline has a very promising portfolio and a strong and thoughtful management team,” said Eef Schimmelpennink. “I welcome the opportunity to join the company on its journey to bring patients new options to address serious neurological disorders.”
Mr. Schimmelpennink currently serves as President and CEO of LENZ Therapeutics, a late-stage clinical company developing innovative ophthalmic pharmaceutical products that aim to improve vision. Prior to LENZ, Mr. Schimmelpennink was CEO and President of Pfenex, Inc. (NYSE: PFNX), up through its acquisition by Ligand Pharmaceuticals in 2020. Before his role at Pfenex, Mr. Schimmelpennink served as CEO for Alvotech, a private specialty biopharmaceutical company. From December 2012 to November 2015, Mr. Schimmelpennink held global marketing and strategy roles at Pfizer and Hospira.
Mr. Schimmelpennink currently serves on the Board of Directors for iBio, Inc. (NYSE:IBIO), where he is the chair of the Nominating and Corporate Governance Committee and a member of the Science and Technology Committee.
Mr. Schimmelpennink obtained his Master of Science in Bioprocess Engineering from Wageningen University & Research, as well as a degree from the Arnhem Business School.
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, including remyelination, synaptogenesis and axonal repair. Pipeline has two product candidates in clinical development: PIPE-307, targeting remyelination to treat multiple sclerosis, which recently completed a Phase 1 healthy volunteer study, and PIPE-505, targeting sensorineural hearing loss associated with speech-in-noise disability, which recently completed a Phase 1/2a study. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit www.pipelinetherapeutics.com.
Chief Financial Officer
Evert (Eef) Schimmelpennink has served as a member of our board of directors since January 2022. Mr. Schimmelpennink is currently the President and Chief Executive Officer of LENZ Therapeutics, a private biotechnology company. From August 2017 to October 2020 he was the Chief Executive Officer of Pfenex Inc. (NYSE: PFNX), which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From October 2015 to July 2017, Mr. Schimmelpennink was Chief Executive Officer of Alvotech, a private specialty biopharmaceutical company, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. Mr. Schimmelpennik also serves on the board of directors of IBio, Inc. (NYSE:iBIO). Mr. Schimmelpennink earned a M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School.
Mike has served as our Senior Director, Corporate Controller since April 2021. Mr. Mayberry previously served as the Senior Director, Accounting for Decipher Biosciences, or Decipher, from July 2020 until their acquisition as of April 2021. Prior to joining Decipher, Mr. Mayberry was the Global Controller for Anaergia and an audit Senior Manager at EY, where he spent ten years in public accounting.
Mike is a Certified Public Accountant in the State of California. He holds a bachelor’s degree in accounting from Pennsylvania State University.
Varsha joined Pipeline in May 2021 and brings over 20 years of experience in biotechnology business development, alliance management, and corporate strategy. Her experience spans in- and out-license agreements, asset purchases and divestments, M&A and financing activities. She joined Pipeline Therapeutics from Secura Bio, where she led business development efforts including the acquisition of Copiktra®, from Verastem Oncology. Varsha previously worked at Synthetic Genomics, Viking Pharmaceuticals, and Amylin Pharmaceuticals (acquired by BMS). Varsha holds an MBA in Technology Transfer and a Master of Science in Neuroscience.
SAN DIEGO, November 12, 2020 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m. ET / 11:00 a.m. PT.
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.